Analyst Price Targets — CRVS
Latest News for CRVS
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12-month
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report)'s stock price fell 6.5% during trading on Friday following a dissappointing earnings announcement. The stock traded as low as $15.12 and last traded at $14.9750. 286,811 shares were traded during trading, a decline of 93% from the average session volume of 3,917,681 shares. The stock had previously
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript
Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRVS.
U.S. House Trading
No House trades found for CRVS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.